Literature DB >> 34363728

Cannabinoids for skin diseases and hair regrowth.

Aditya K Gupta1,2, Mesbah Talukder2.   

Abstract

The use of cannabis for skin diseases and hair regrowth is at the preliminary stage. LEGALIZATION: Many countries have approved cannabis for medical use; however, four countries Canada, Uruguay, South Africa, and Georgia have legalized it for both medical and recreational purposes. THE ENDOCANNABINOID SYSTEM: The endocannabinoid system may maintain skin homeostasis; two notable endocannabinoids include 2-Arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA). ROUTES OF ADMINISTRATION AND PHARMACOKINETICS: Topical cannabinoids can avoid the first-pass metabolism and reduce respiratory side effects; however, the high hydrophobicity of cannabinoids may hinder percutaneous absorption. SKIN DISORDERS AND HAIR GROWTH: Human clinical studies suggest that cannabinoids may be used in eczema, acne, pruritus, and systemic sclerosis treatment. Cannabidiol (CBD) may enhance hair growth via multiple mechanisms. SAFETY: Topical cannabis may cause mild side effects such as pruritus, burning, erythema, and stinging; they are relatively safer than inhalation and oral cannabis. Cannabis use may be associated with allergic symptoms and reduced immune response to live vaccination. CANNABINOIDS IN PRACTICE: Despite growing interest, dermatologists should be cautious prescribing cannabinoids due to insufficient clinical data on both efficacy and safety.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  cannabidiol; cannabinoids; endocannabinoid system; hair growth; skin diseases

Year:  2021        PMID: 34363728     DOI: 10.1111/jocd.14352

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  2 in total

1.  Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology.

Authors:  Jennifer Laborada; Philip R Cohen
Journal:  Cureus       Date:  2022-04-05

2.  In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.

Authors:  Eduardo Perez; Jose R Fernandez; Corey Fitzgerald; Karl Rouzard; Masanori Tamura; Christopher Savile
Journal:  Molecules       Date:  2022-01-13       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.